OPT 6.43% 65.5¢ opthea limited

This is the first of 6 x phase III trials for Kodiak and while...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 514 Posts.
    lightbulb Created with Sketch. 80
    This is the first of 6 x phase III trials for Kodiak and while the company maybe able to argue poor trial design in this case what could be the killer in the long run is a 3.2% intraoccular inflammation rate compared to Eylea’s 0% in this trial. A high intraoccular inflammation rate of 4% for Novartis’ drug Beovu has been a safety worry which has clearly weighed significantly on the drug’s commercial success.
 
watchlist Created with Sketch. Add OPT (ASX) to my watchlist
(20min delay)
Last
65.5¢
Change
-0.045(6.43%)
Mkt cap ! $806.3M
Open High Low Value Volume
69.5¢ 69.5¢ 63.0¢ $2.808M 4.305M

Buyers (Bids)

No. Vol. Price($)
1 49996 65.5¢
 

Sellers (Offers)

Price($) Vol. No.
66.0¢ 50869 6
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
OPT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.